ECONOMIC OUTCOMES OF EMICIZUMAB IN MANAGING HAEMOPHILIA A AMONG CHILDREN AND ADULTS IN THE UAE: MONETIZATION OF A RETROSPECTIVE ANALYSIS CONDUCTED AT TAWAM HOSPITAL AND SHEIKH KHALIFA MEDICAL CITY
Author(s)
Khaled Al Qawasmeh, MSc1, Waiel Al Naeem, MSc2, Sana Alblooshi, MBA1, Alaa Farahat, MSc3, Mahmoud Wael, MSc4.
1Tawam Hospital, Al Ain, United Arab Emirates, 2Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates, 3AWE Research, Riyadh, Saudi Arabia, 4Roche Pharmaceuticals Middle East FZCO, Dubai, United Arab Emirates.
1Tawam Hospital, Al Ain, United Arab Emirates, 2Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates, 3AWE Research, Riyadh, Saudi Arabia, 4Roche Pharmaceuticals Middle East FZCO, Dubai, United Arab Emirates.
OBJECTIVES: An economic evaluation was conducted to assess the financial impact of Emicizumab compared with other haemophilia A (HA) treatment regimens using data from a retrospective observational study at Tawam Hospital and Sheikh Khalifa Medical City (SKMC) in the UAE. The analysis included all paediatric and adult HA patients who received Emicizumab or alternative regimens between January 2019 and December 2023. The study aimed to monetize direct costs, including prophylaxis, management of bleeding and joint bleeding episodes, FVIII assays, and missed doses, as well as indirect costs related to absenteeism, productivity losses, and missed prophylaxis at Tawam and SKMC hospitals.
METHODS: Clinical outcomes for the cost analysis were extracted from the retrospective study by Al Rufaye et al. (2025). In-depth interviews were conducted with payers from both tertiary hospitals to capture the costs healthcare resources utilised and management of each bleeding episode and joint bleed, absenteeism and productivity losses experienced by the patient, and other relevant resources. Prophylactic treatment regimens were calculated based on the Summary of Product Characteristics (SmPC) dosages and frequencies, public prices and payer opinions.
RESULTS: The retrospective study reported that Emicizumab significantly improved clinical outcomes, with the annualized bleeding rate (ABR) reduced from 2.9 ± 2.4 prior to treatment to 0.0 ± 0.0 following initiation (p < 0.001). Total direct costs across hospitals decreased by 26%, corresponding to savings of AED 411,023 per patient, mainly driven by reduced costs of bleeding events and joint bleeding episodes. Indirect costs related to missed prophylaxis, absenteeism, and productivity losses totaled AED 4,195,066 annually before Emicizumab, with no indirect costs observed after treatment initiation across both hospitals.
CONCLUSIONS: Adoption of Emicizumab in both hospitals demonstrated economic benefits by reducing prophylaxis and bleeding management costs, highlighting its value from a payer perspective for optimizing haemophilia A management in the UAE.
METHODS: Clinical outcomes for the cost analysis were extracted from the retrospective study by Al Rufaye et al. (2025). In-depth interviews were conducted with payers from both tertiary hospitals to capture the costs healthcare resources utilised and management of each bleeding episode and joint bleed, absenteeism and productivity losses experienced by the patient, and other relevant resources. Prophylactic treatment regimens were calculated based on the Summary of Product Characteristics (SmPC) dosages and frequencies, public prices and payer opinions.
RESULTS: The retrospective study reported that Emicizumab significantly improved clinical outcomes, with the annualized bleeding rate (ABR) reduced from 2.9 ± 2.4 prior to treatment to 0.0 ± 0.0 following initiation (p < 0.001). Total direct costs across hospitals decreased by 26%, corresponding to savings of AED 411,023 per patient, mainly driven by reduced costs of bleeding events and joint bleeding episodes. Indirect costs related to missed prophylaxis, absenteeism, and productivity losses totaled AED 4,195,066 annually before Emicizumab, with no indirect costs observed after treatment initiation across both hospitals.
CONCLUSIONS: Adoption of Emicizumab in both hospitals demonstrated economic benefits by reducing prophylaxis and bleeding management costs, highlighting its value from a payer perspective for optimizing haemophilia A management in the UAE.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE124
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)